Melanoma Immunotherapy: What’s Next for Patients?

On May 12, 2015, Antoni Ribas, M.D., Ph.D., provided an update on cancer immunotherapy and how to maximize it to treat melanoma. He discussed the immunotherapies that are FDA approved—including Yervoy, Keytruda, and Opdivo—or in the late stages of clinical development and the potential future roles of cancer immunotherapy, including data that suggests that immune therapies can be combined with other types of therapies. He also addressed when to use and not to use immunotherapy and provided data about what to expect clinically from this type of treatment.

This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This webinar was made possible by the generous support of Amgen. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.